Anipamil is a long-acting blocker of calcium channel,and for the treatment of cardiovascular disease.

Anipamil inhibits the growth of SMC accompanied by the expression of SM-MyHC in all SMC, ie, the appearance of a more differentiated cell phenotype compared to control cultures[1]. Anipamil (40 mg, p.o.)-treated 2K-1C rabbits reveal absent or negligible intimal thickening and a decrease of postnatal-type SMC from the underlying media. The anipamil (2 mg/kg/day)-treated group exhibits significantly greater protection of renal function than does the hydralazine-treated group for the same level of blood pressure control[3]. In the arrhythmic assay, anipamil (1.0 mg/kg + 0.10 mg/kg/min infusion, n=8 or 5.0 mg/kg + 0.50 mg/kg/min infusion, n=12) reduces VT but not VF[2]. In rats with subtotal (five-sixths) nephrectomy treated with anipamil (0.5 mg/kg/day, p.o.), the mortality is less, and the mean arterial blood pressure is also more well controlled, and the serum creatinine concentration is lower than control group.